MADRID, Spain – Two phase III trials accepted as late-breaking abstracts for the European Society for Medical Oncology (ESMO) 2017 Congress showed abemaciclib reduced the risk of disease progression by 46 percent in advanced breast cancer and Cyramza (ramucirumab) improved progression-free survival (PFS) when added to docetaxel in advanced or metastatic urothelial cancer.